TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

503

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2027

Conditions

Triple Negative Breast CancerBreast Cancer

Interventions

DRUG

docetaxel

DRUG

doxorubicin or epirubicin

DRUG

cyclophosphamide

DRUG

gemcitabine

DRUG

cisplatin

Trial Locations (1)

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER

NCT02641847 - TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature | Biotech Hunter | Biotech Hunter